Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03106779 · OUTCOME

Time to Treatment Failure (TTF)

Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs · Source last updated 2026-08-18

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
Year
Interval / dispersion
95% Confidence Interval
Time frame
From the first dose of treatment up to 5 years, through treatment completion, an average of 2.3 years, approximately

What was measured

TTF was defined as the time from date of randomization to an event of treatment failure. Treatment failure was defined as meeting a lack of efficacy criterion or discontinuing treatment due to any reason.

Analysis population: Full Analysis Set (FAS): The FAS comprised of all randomized participants.

Groups in this outcome

Asciminib

Participants randomized to asciminib 40mg BID

Bosutinib

Participants randomized to bosutinib 500mg QD

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Asciminib157
Bosutinib76

Reported measurements

Source class 1
Values in Year · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Asciminib2.4Not reported1.0NANA: Not estimable due to insufficient events observed
Bosutinib0.5Not reported0.50.6Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. comment
        NA: Not estimable due to insufficient events observed
        group Id
        OG000
        lower Limit
        1.0
        upper Limit
        NA
        value
        2.4
      2. group Id
        OG001
        lower Limit
        0.5
        upper Limit
        0.6
        value
        0.5
denoms
  1. counts
    1. group Id
      OG000
      value
      157
    2. group Id
      OG001
      value
      76
    units
    Participants
description
TTF was defined as the time from date of randomization to an event of treatment failure. Treatment failure was defined as meeting a lack of efficacy criterion or discontinuing treatment due to any reason.
dispersion Type
95% Confidence Interval
groups
  1. description
    Participants randomized to asciminib 40mg BID
    id
    OG000
    title
    Asciminib
  2. description
    Participants randomized to bosutinib 500mg QD
    id
    OG001
    title
    Bosutinib
param Type
MEDIAN
population Description
Full Analysis Set (FAS): The FAS comprised of all randomized participants.
reporting Status
POSTED
time Frame
From the first dose of treatment up to 5 years, through treatment completion, an average of 2.3 years, approximately
title
Time to Treatment Failure (TTF)
type
SECONDARY
unit Of Measure
Year

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice